Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T van Putten

Showing results (71-80 of 103) with videos related to

Pageof 11
Sort By:
Archives of General Psychiatry|September 1, 1988
Differential effect of low and conventional doses of fluphenazine on schizophrenic outpatients with good or poor information-processing abilitiesR F Asarnow, S R Marder, J Mintz, et al.
Journal of Clinical Psychopharmacology|October 1, 1990
Effects of clozapine on treatment-resistant akathisia and concomitant tardive dyskinesiaW C Wirshing, C K Phelan, T van Putten, et al.
Archives of General Psychiatry|February 1, 1981
Chlorpromazine levels and the outcome of treatment in schizophrenic patientsP R May, T Van Putten, D J Jenden, et al.
Archives of General Psychiatry|July 1, 1992
Fluoxetine, akathisia, and suicidality: is there a causal connection?W C Wirshing, T Van Putten, J Rosenberg, et al.
Psychopharmacology Bulletin|January 1, 1985
Plasma levels of haloperidol and clinical responseT Van Putten, S R Marder, P R May, et al.
Journal of Psychiatry & Neuroscience : JPN|July 1, 1994
Impact of clinical pharmacokinetics on neuroleptic therapy in patients with schizophreniaK K Midha, J W Hubbard, S R Marder, et al.
Psychopharmacology|January 1, 1983
Plasma levels of thiothixene by radioreceptor assay: clinical usefulnessT Van Putten, P R May, S R Marder, et al.
International Journal of Law and Psychiatry|January 1, 1986
Consent and liability with neuroleptics: the problem of tardive dyskinesiaM J Mills, G S Norquist, R C Shelton, et al.
Psychopharmacology Bulletin|January 1, 1991
Plasma fluphenazine levels and clinical response in newly admitted schizophrenic patientsT Van Putten, M Aravagiri, S R Marder, et al.
Archives of General Psychiatry|June 1, 1987
Low- and conventional-dose maintenance therapy with fluphenazine decanoate. Two-year outcomeS R Marder, T Van Putten, J Mintz, et al.
Pageof 11

Showing results (71-80 of 103) with videos related to

Sort By:
Pageof 11
Archives of General Psychiatry|September 1, 1988
Differential effect of low and conventional doses of fluphenazine on schizophrenic outpatients with good or poor information-processing abilitiesR F Asarnow, S R Marder, J Mintz, et al.
Journal of Clinical Psychopharmacology|October 1, 1990
Effects of clozapine on treatment-resistant akathisia and concomitant tardive dyskinesiaW C Wirshing, C K Phelan, T van Putten, et al.
Archives of General Psychiatry|February 1, 1981
Chlorpromazine levels and the outcome of treatment in schizophrenic patientsP R May, T Van Putten, D J Jenden, et al.
Archives of General Psychiatry|July 1, 1992
Fluoxetine, akathisia, and suicidality: is there a causal connection?W C Wirshing, T Van Putten, J Rosenberg, et al.
Psychopharmacology Bulletin|January 1, 1985
Plasma levels of haloperidol and clinical responseT Van Putten, S R Marder, P R May, et al.
Journal of Psychiatry & Neuroscience : JPN|July 1, 1994
Impact of clinical pharmacokinetics on neuroleptic therapy in patients with schizophreniaK K Midha, J W Hubbard, S R Marder, et al.
Psychopharmacology|January 1, 1983
Plasma levels of thiothixene by radioreceptor assay: clinical usefulnessT Van Putten, P R May, S R Marder, et al.
International Journal of Law and Psychiatry|January 1, 1986
Consent and liability with neuroleptics: the problem of tardive dyskinesiaM J Mills, G S Norquist, R C Shelton, et al.
Psychopharmacology Bulletin|January 1, 1991
Plasma fluphenazine levels and clinical response in newly admitted schizophrenic patientsT Van Putten, M Aravagiri, S R Marder, et al.
Archives of General Psychiatry|June 1, 1987
Low- and conventional-dose maintenance therapy with fluphenazine decanoate. Two-year outcomeS R Marder, T Van Putten, J Mintz, et al.
Pageof 11